Melinta Drug Patent Portfolio
Melinta owns 3 orange book drugs protected by 21 US patents Given below is the list of Melinta's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649352 | High purity oritavancin and method of producing same | 16 Jul, 2035 | Active |
| US12036219 | Methods of treating infections in overweight and obese patients using antibiotics | 02 Jun, 2034 | Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 27 Feb, 2033 | Active |
| US12138257 | Antimicrobial compositions | 01 May, 2032 | Active |
| US7728143 | Salt and crystalline forms thereof of a drug | 19 Jun, 2031 | Active |
| US9682061 | Methods of treating bacterial infections using oritavancin | 26 Apr, 2030 | Active |
| US8497378 | Process for making quinolone compounds | 28 Dec, 2029 | Active |
| USRE46617 | Process for making quinolone compounds | 28 Dec, 2029 | Active |
| US8871938 | Process for making quinolone compounds | 23 Sep, 2029 | Active |
| US8420592 | Methods of treatment using single doses of oritavancin | 29 Aug, 2029 | Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8252813 | Salt and crystalline forms thereof of a drug | 02 Oct, 2026 | Active |
| US8273892 | Salt and crystalline forms thereof of a drug | 06 Aug, 2026 | Active |
| US8648093 | Salt and crystalline forms thereof of a drug | 07 Oct, 2025 | Expired |
| US8969569 | Salt and crystalline forms thereof of a drug | 07 Oct, 2025 | Expired |
| US9539250 | Salt and crystalline forms thereof of a drug | 07 Oct, 2025 | Expired |
| US5840684 | Glycopeptide antibiotic derivatives | 24 Nov, 2020 | Expired |
| US5998581 | Reductive alkylation of glycopeptide antibiotics | 12 Nov, 2017 | Expired |
Latest Legal Activities on Melinta's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Melinta.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9539250 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2024 | US8273892 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2024 | US8252813 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 May, 2023 | US9200088 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9750822 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9493582 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9200088 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US8410077 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US7635773 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Aug, 2022 | US8969569 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2022 | US8871938 |
|
Withdrawal of Application for PTE
Critical
| 07 Mar, 2022 | US8252813 |
|
Patent Term Extension Certificate
Critical
| 07 Mar, 2022 | US7728143 |
| Notice of Final Determination -Election Required | 08 Dec, 2021 | US8252813 |
Melinta Drug Patents' Oppositions Filed in EPO
Melinta drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 13, 2017, by Prüfer & Partner Mbb. This opposition was filed on patent number EP09810708A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP09810708A | Jan, 2017 | Prüfer & Partner mbB | Granted and Under Opposition |
Melinta's Family Patents
Melinta Drug List
Given below is the complete list of Melinta's drugs and the patents protecting them.
1. Baxdela
Baxdela is protected by 16 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12036219 | Methods of treating infections in overweight and obese patients using antibiotics |
02 Jun, 2034
(8 years from now)
| Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
27 Feb, 2033
(7 years from now)
| Active |
| US12138257 | Antimicrobial compositions |
01 May, 2032
(6 years from now)
| Active |
| US7728143 | Salt and crystalline forms thereof of a drug |
19 Jun, 2031
(5 years from now)
| Active |
| US8497378 | Process for making quinolone compounds |
28 Dec, 2029
(3 years from now)
| Active |
| USRE46617 | Process for making quinolone compounds |
28 Dec, 2029
(3 years from now)
| Active |
| US8871938 | Process for making quinolone compounds |
23 Sep, 2029
(3 years from now)
| Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US8252813 | Salt and crystalline forms thereof of a drug |
02 Oct, 2026
(8 months from now)
| Active |
| US8273892 | Salt and crystalline forms thereof of a drug |
06 Aug, 2026
(6 months from now)
| Active |
| US8648093 | Salt and crystalline forms thereof of a drug |
07 Oct, 2025
(3 months ago)
| Expired |
| US8969569 | Salt and crystalline forms thereof of a drug |
07 Oct, 2025
(3 months ago)
| Expired |
| US9539250 | Salt and crystalline forms thereof of a drug |
07 Oct, 2025
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Baxdela's drug page
2. Kimyrsa
Kimyrsa is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649352 | High purity oritavancin and method of producing same |
16 Jul, 2035
(9 years from now)
| Active |
| US9682061 | Methods of treating bacterial infections using oritavancin |
26 Apr, 2030
(4 years from now)
| Active |
| US8420592 | Methods of treatment using single doses of oritavancin |
29 Aug, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kimyrsa's drug page
3. Orbactiv
Orbactiv is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649352 | High purity oritavancin and method of producing same |
16 Jul, 2035
(9 years from now)
| Active |
| US9682061 | Methods of treating bacterial infections using oritavancin |
26 Apr, 2030
(4 years from now)
| Active |
| US8420592 | Methods of treatment using single doses of oritavancin |
29 Aug, 2029
(3 years from now)
| Active |
| US5840684 | Glycopeptide antibiotic derivatives |
24 Nov, 2020
(5 years ago)
| Expired |
| US5998581 | Reductive alkylation of glycopeptide antibiotics |
12 Nov, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orbactiv's drug page